Inflammatory Bowel Disease · Article 135

When Has IV Steroid Therapy Failed in Acute Severe Ulcerative Colitis?

Acute severe UC steroids requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

Acute severe UC steroids clinical reference — Related free clinical resource: First Principles of Gastroenterology and Hepatology.

Acute severe UC steroids: practical clinical approach

This page focuses on Acute severe UC steroids with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for Acute severe UC steroids

Clinical takeaway: For Acute severe UC steroids, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: IV steroid response in ASUC should be judged early. Persistent high stool frequency, ongoing significant rectal bleeding, elevated or rising CRP, worsening anemia, fever, tachycardia, abdominal distention or other toxicity by approximately day 3 indicate inadequate response. The 2025 ACG guideline recommends rescue therapy with infliximab or cyclosporine when adequate response has not occurred by three days. Steroid failure should not be managed by simply extending IV steroids while the patient deteriorates.

Use objective daily measures

Record stool frequency and bleeding, vital signs, abdominal findings, hemoglobin and serial CRP. Classic indices such as the Oxford day-3 criteria remain useful for predicting colectomy risk.

Rule out treatable contributors

Confirm C. difficile testing, review CMV histology/biopsies when indicated, correct electrolytes and assess for megacolon or perforation.

Failure is a clinical decision, not one number

A patient with persistent bloody stools and systemic toxicity can require escalation even if one biomarker improves.

Practical clinical algorithm

Start IV steroids at an adequate guideline dose.
Track objective response daily.
Reassess infection and complications.
By day 3, classify response as adequate or inadequate.
If inadequate, initiate infliximab/cyclosporine rescue and obtain surgical consultation.
Do not delay colectomy for perforation, megacolon or uncontrolled hemorrhage.

Common mistakes to avoid

Waiting for day 7 to decide.
Using CRP alone.
Ignoring stool frequency trends.
Escalating steroid dose indefinitely.
Delaying surgery because rescue therapy was just given.

Trainee takeaway

Day 3 is the key checkpoint: if meaningful clinical improvement is absent, continuing steroids alone is no longer an adequate strategy.

Frequently asked questions

What are the Oxford criteria?

A classic day-3 combination of stool frequency and CRP used to estimate colectomy risk.

Can response be judged before day 3?

Yes, deterioration or toxicity can force earlier action.

Should rescue therapy wait for complete CMV results?

The decision is individualized; severe deterioration should not be allowed while awaiting nonessential delays.

References

1. Thomson ABR. Guideline-Based Management in Gastroenterology. CAPstone Academic Publishers; 2015.

2. Thomson ABR. Practice Review in Gastroenterology. CAPstone Academic Publishers; 2014.

3. Rubin DT, et al. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. Am J Gastroenterol. 2025;120:1187-1224.

4. Travis SPL, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905-910.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions